Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 19

1.

Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.

Grindel B, Li Q, Arnold R, Petros J, Zayzafoon M, Muldoon M, Stave J, Chung LW, Farach-Carson MC.

Oncotarget. 2016 Mar 1;7(9):10433-47. doi: 10.18632/oncotarget.7197.

2.

Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth.

Sung SY, Wu IH, Chuang PH, Petros JA, Wu HC, Zeng HJ, Huang WC, Chung LW, Hsieh CL.

Oncotarget. 2014 Oct 30;5(20):9911-29.

3.

Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions.

Sreedharan S, Petros JA, Master VA, Ogan K, Pattaras JG, Roberts DL, Lian F, Arnold RS.

Dis Markers. 2014;2014:135649. doi: 10.1155/2014/135649. Epub 2014 Apr 6.

4.

Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.

Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, Gillespie T, Park JY, Nam RK, Sugar L, Stanimirovic A, Seth AK, Petros JA, Moreno CS.

Cancer Res. 2014 Jun 15;74(12):3228-37. doi: 10.1158/0008-5472.CAN-13-2699. Epub 2014 Apr 8.

5.

An inherited heteroplasmic mutation in mitochondrial gene COI in a patient with prostate cancer alters reactive oxygen, reactive nitrogen and proliferation.

Arnold RS, Sun Q, Sun CQ, Richards JC, O'Hearn S, Osunkoya AO, Wallace DC, Petros JA.

Biomed Res Int. 2013;2013:239257. doi: 10.1155/2013/239257. Epub 2012 Dec 27.

6.

Pelvic nephroureterectomy for renal cell carcinoma in an ectopic kidney.

Baldie KG, Al-Qassab UA, Ritenour CW, Issa MM, Osunkoya AO, Petros JA.

Case Rep Oncol Med. 2012;2012:350916. doi: 10.1155/2012/350916. Epub 2012 Oct 22.

7.

Mitochondrial Cytochrome c Oxidase subunit 1 Sequence Variation in Prostate Cancer.

Scott TA, Arnold R, Petros JA.

Scientifica (Cairo). 2012;2012:701810.

8.

Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.

Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, Stanimirovic A, Williams DJ, Leyland-Jones BR, Seth AK, Petros JA, Moreno CS.

Am J Pathol. 2011 Jul;179(1):46-54. doi: 10.1016/j.ajpath.2011.03.008. Epub 2011 May 3.

9.

Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer.

Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, Liotta DC.

ACS Med Chem Lett. 2011 Mar 25;2(6):438-43. doi: 10.1021/ml2000164. eCollection 2011 Jun 9.

10.

Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model.

Makarova N, Zhao C, Zhang Y, Bhosle S, Suppiah S, Rhea JM, Kozyr N, Arnold RS, Ly H, Molinaro RJ, Parslow TG, Hunter E, Liotta D, Petros J, Blackwell JL.

PLoS One. 2011 Apr 6;6(4):e18272. doi: 10.1371/journal.pone.0018272. Erratum in: PLoS One. 2011;6(5). doi:10.1371/annotation/913fdc1e-877e-4c70-ac20-761d2d72400d.

11.

Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells.

Bhosle S, Suppiah S, Molinaro R, Liang Y, Arnold R, Diehl W, Makarova N, Blackwell J, Petros J, Liotta D, Hunter E, Ly H.

J Virol. 2010 Jul;84(13):6288-96. doi: 10.1128/JVI.00274-10. Epub 2010 Apr 21.

12.

Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots.

Liu J, Lau SK, Varma VA, Moffitt RA, Caldwell M, Liu T, Young AN, Petros JA, Osunkoya AO, Krogstad T, Leyland-Jones B, Wang MD, Nie S.

ACS Nano. 2010 May 25;4(5):2755-65. doi: 10.1021/nn100213v.

13.

Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men.

Ray AM, Zuhlke KA, Levin AM, Douglas JA, Cooney KA, Petros JA.

Prostate. 2009 Jun 15;69(9):956-60. doi: 10.1002/pros.20943.

14.

Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.

Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA.

Prostate. 2009 Jan 1;69(1):1-11. doi: 10.1002/pros.20854.

15.

SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE, Dong JT.

Hum Mol Genet. 2008 Apr 1;17(7):1031-42. doi: 10.1093/hmg/ddm375. Epub 2008 Jan 17.

16.

Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1.

Arnold RS, He J, Remo A, Ritsick D, Yin-Goen Q, Lambeth JD, Datta MW, Young AN, Petros JA.

Am J Pathol. 2007 Dec;171(6):2021-32. Epub 2007 Nov 30.

17.

Molecular classification of renal tumors by gene expression profiling.

Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, Hornsby CD, Yang WL, Petros JA, Issa MM, Pattaras JG, Ogan K, Marshall FF, Young AN.

J Mol Diagn. 2005 May;7(2):206-18.

18.

mtDNA mutations increase tumorigenicity in prostate cancer.

Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24. Epub 2005 Jan 12.

19.

Reactive oxygen generated by Nox1 triggers the angiogenic switch.

Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD.

Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk